Zusammenfassung
Die Vielfalt der angebotenen Medikamente zur Behandlung von dyspeptischen Beschwerden ist ein Hinweis auf das Fehlen einer wirklich befriedigenden medikamentösen Therapie. Der Wirkungsnachweis ist schwierig zu erbringen, denn gut die Hälfte der dyspeptischen Patienten spricht zumindest vorübergehend auf eine Plazebotherapie an. Zudem sind funktionelle Dyspepsien chronische Erkrankungen mit rezidivierendem Verlauf. Verschiedene pathophysiologische Mechanismen sind für die Erkrankungen verantwortlich. Ein einzelner Mechanismus kann verschiedenartige Symptome verursachen, und einem einzelnen Symptom können unterschiedliche Mechanismen zugrunde liegen (1). Da die eigentlichen Ursachen der Erkrankung unbekannt sind, ist eine kausale Therapie zur Zeit nicht möglich.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literature
Ausgewählte Arbeiten von besonderem Interesse
Dobrilla G, Comberlato M, Steele A, Vallaperta P (1989) Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 11:169–177.Metaanalytische Auswertung von 23 kontrollierten, randomisierten Studien über die medikamentöse Therapie der funktionellen Dyspepsien. Bei Dyspepsie des UlkusTyps sind Säuresekretionshemmer und bei der Dyspepsie des Dysmotilitäts-Typs Prokinetika wirksam. 62 zitierte Arbeiten.
Zitierte Arbeiten
Bonfils S, Phuoc KN, Rene E (1988) Non-ulcerous dyspepsia. Toward a rational approach in therapeutic studies. Gastroenterol Clin Biol 12:187–192.
Goodson JD, Richter JM, Lane RS, Beckett TF, Pingree RG (1986) Empiric antacids and reassurance for acute dyspepsia. J Gen Intern Med 1:90–93.
Berstad A, Alexander B, Weberg R, Serck-Hanssen A, Holland S, Hirschowitz BI (1988) Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes. Gastroenterology 95:619–624.
Uzan M, Uzan S, Sureau C, Richard Berthe C (1988) Pyrosis et regurgitations au cours de la grossesse. Efficacité et innocuité d’un traitement par Gaviscon suspension. Rev Fr Gynecol Obstet 83: 569–572.
Dimethicone for gastrointestinal symptoms? Drug Ther Bull 1986; 24: 21–22.
Camilleri M, Malagelada JR, Abell TL, Brown ML, Hench V, Zinsmeister A (1989) Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 96:704–712.
Testoni PA, Bagnolo F, Fanti L, Passaretti S, Tittobello A (1990) Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 31:288–290.
Valori RM, Kumar D, Wingate DL (1986) Effects of different types of stress and of „prokinetic“ drugs on the control of the fasting motor complex in humans. Gastroenterology 1986; 90:1890–1900.
Karnad DR, Abraham P, Rathod NM, Nazareth HM (1990) Test for H2-antagonist response in non-ulcer dyspepsia. Lancet 335:657–658.
Nyren O, Adami HO, Bates S, Bergstrom R, Gustavsson S, Loof L, Nyberg A (1986) Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 314:339–343.
Burks TF (1987) Actions of drugs on gastrointestinal motility. In: Johnson LR., ed. Physiology of the Gastrointestinal Tract. New York: Raven Press, 723–743.
Albibi R, McCallum RW (1983) Metoclopramide: pharmacology and clinical application. Ann Intern Med 98:86–95.
Champion MC (1988) Minireview: Domperidone. Gen Pharmac 19:499–505.
McCallum RW, Prakash C, Campoli-Richards DM, Goa KL (1988) Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36: 652–681.
Davis RH, Clench MH, Mathias JR (1988) Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. Dig Dis Sci 33:1505–1511.
Rösch W (1989) Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia. Scand J Gastroenterol Suppl 165P 54–8
Bennett JR (1989) How safe and acceptable is cisapride? Scand J Gastroenterol Suppl 24:59–61.
Verlinden M (1990) Dose-finding of cisapride in non-ulcer dyspepsia. Z Gastroenterol 28 [Suppl 1P] 31–5
Blum AL, Verlinden M (1990) Cisapride prevents relapse of reflux esophagitis. Gastroenterology 1990; 98:A22. (Abstract)
Talley NJ, McNeil D, Hayden A, Piper DW (1986) Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 91:149–156.
Saunders JH, Oliver RJ, Higson DL (1986) Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J [Clin Res] 292:665–668.
Weberg R, Berstad A (1988) Low-dose antacids and pirenzepine in the treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A randomized, double-blind, placebo-controlled trial. Scand J Gastroenterol 23:237–243.
Gad A, Dobrilla G (1989) Campylobacter pylori and non-ulcer dyspepsia. 1. The final results of a double-blind multicentre trial for treatment with pirenzepine in Italy. Scand J Gastroenterol Suppl 167P 39–43
Rokkas T, Pursey C, Uzoechina E, Dorrington L, Simmons NA, Filipe MI, Sladen GE (1988) Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut 29:1386–1391.
Kang JY, Tay HH, Wee A, Guan R, Math MV, Yap I (1990) Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut 31:476–480.
Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R (1990) Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 322:1028–1031.
Kleveland PM, Johannessen T, Kristensen P, Lge I, Sandbakken P, Dybdahl J, Petersen H (1990) Effect of pancreatic enzymes in non-ulcer dyspepsia. A pilot study. Scand J Gastroenterol 25:298–301
Töndury GD (1981) Die Behandlung eines Syndroms von dyspeptischen Beschwerden mit Ursodesoxycholsure. Schweiz Rundsch Med Prax 70:969–973.
Marzio L, Neri M, De Angelis C, Di Felice F, Celiberti V, Pieramico O, Mezzeti A, Cuccurullo F (1987) Effect of cisapride on gallbladder kinetics in normals and patients with decreased gallbladder response to a liquid meal. Curr Ther Res 42:895–900.
Staritz M, Poralla T, Ewe K, Meyer zum Büschenfelde KH (1985) Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut 26: 194–197.
Guelrud M, Mendoza S, Rossiter G, Ramirez L, Barkin J (1988) Effect of nifedipine on sphincter of Oddi motor activity: studies in healthy volumteers and patients with biliary dyskinesia. Gastroenterology 95:1050–1055.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Blum, A.L., Scalfaro, P., Koelz, H.R. (1992). Medikamentöse Therapie. In: Dyspepsiealmanach. Interdisziplinäre Gastroenterologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76906-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-76906-1_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-54517-0
Online ISBN: 978-3-642-76906-1
eBook Packages: Springer Book Archive